2,2-dimethyl-3,4-dihydro-2H-pyran | 931-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环化合物
• 英文名称: 2,2-dimethyl-3,4-dihydro-2H-pyran
• 英文别名: Dimethyldihydropyran；2,2-dimethyl-3,4-dihydropyran
• CAS: 931-79-3
• 化学式: C₇H₁₂O
• 分子量: 112.172
• InChiKey: SYTWCNXJNPSFQT-UHFFFAOYSA-N

物化性质

• 沸点：
  52-58 °C(Press: 100 Torr)
• 密度：
  0.868±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-3,4-dihydro-2H-pyran 在 镍 作用下， 75.0 ℃ 、9.81 MPa 条件下， 生成 2,2-dimethyltetrahydropyran
  参考文献：
  名称：

  Reactions of Acrolein and Related Compounds. I. Addition of Vinyl Ethers

  摘要：

  DOI：

  10.1021/ja01155a076
• 作为产物：
  描述：

  6,6-Dimethyl-tetrahydro-pyran-2-ol 在 aluminum oxide 作用下， 生成 2,2-dimethyl-3,4-dihydro-2H-pyran
  参考文献：
  名称：

  马尿酸的螺酮基团对抗增殖活性的结构和立体化学要求

  摘要：

  Hippuristanol 是一种天然产物，最近已被证明可以抑制真核翻译起始和肿瘤细胞增殖。为了研究马尿酸的结构和活性关系，我们通过扩大其 F 环的大小合成了一系列类似物，并确定了它们对癌细胞系增殖的影响。hippuristanol 的 F 环的所有变化导致活性降低 3 倍至 >100 倍。

  DOI：

  10.1016/j.bmcl.2010.03.093

文献信息

• [EN] N-PYRIDINYL ACETAMIDE DERIVATIVES AS WNT SIGNALLING PATHWAY INHIBITORS<br/>[FR] DÉRIVÉS N-PYRIDINYL ACÉTAMIDE COMME INHIBITEURS DE LA OIE DE SIGNALISATION WNT
  申请人：REDX PHARMA PLC

  公开号：WO2016055790A1

  公开（公告）日：2016-04-14

  This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  这项发明涉及化合物。更具体地，该发明涉及作为Wnt信号通路抑制剂的化合物。具体来说，该发明考虑了Porcupine（Porcn）的抑制剂。此外，该发明考虑了制备这些化合物的过程以及这些化合物的用途。因此，该发明的化合物可用于治疗由Wnt信号通路介导的疾病，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌症和白血病；或增强抗癌治疗的有效性。
• [EN] N-PYRIDINYL ACETAMIDE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY<br/>[FR] DÉRIVÉS DE N-PYRIDYL ACÉTAMIDE UTILISÉS COMME INHIBITEURS DE LA VOIE DE SIGNALISATION WNT
  申请人：REDX PHARMA PLC

  公开号：WO2016055786A1

  公开（公告）日：2016-04-14

  This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.

  这项发明涉及化合物。更具体地，该发明涉及作为Wnt信号通路抑制剂的化合物。具体来说，该发明考虑了Porcupine（Porcn）的抑制剂。此外，该发明考虑了制备这些化合物的过程以及这些化合物的用途。因此，该发明的化合物可用于治疗由Wnt信号通路介导的疾病，例如治疗癌症、肉瘤、黑色素瘤、皮肤癌、血液肿瘤、淋巴瘤、癌症和白血病；或增强抗癌治疗的有效性。
• A Versatile Enantioselective Catalytic Cyclopropanation‐Rearrangement Approach to the Divergent Construction of Chiral Spiroaminals and Fused Bicyclic Acetals
  作者：Li Zhou、Wen‐Guang Yan、Xiu‐Li Sun、Lijia Wang、Yong Tang

  DOI：10.1002/anie.202007068

  日期：2020.10.19

  A highly enantioselective synthesis of various chiral heterobicyclic molecules including spiroaminals and fused bicyclic acetals has been developed via a chiral copper catalyzed cyclopropanation‐rearrangement (CP‐RA) approach under mild reaction conditions. Remarkably, the asymmetric CP‐RA for exocyclic vinyl substrates without a pro‐stereogenic carbon at the β‐position has been realized for the first

  在温和的反应条件下，通过手性铜催化的环丙烷重排（CP-RA）方法开发了各种手性杂环双环分子，包括螺氨基化合物和稠合双环缩醛的高度对映选择性合成。引人注目的是，首次实现了在β-位上没有前体成因碳的环外乙烯基底物的不对称CP-RA，并在广泛的底物范围内实现了优异的结果（33例；产率34-99％；> 95 /已达到5 dr和91–99％ee）。还介绍了一种连续对映选择性CP‐RA方法的应用，提供了对复杂手性杂多环的简明访问。
• A PROCESS FOR PRODUCING GAMMA MANGOSTIN
  申请人：Gokaraju Ganga Raju

  公开号：US20100292490A1

  公开（公告）日：2010-11-18

  A process for the production of γ-mangostin comprising the steps of preparing O-methyl γ-mangostin preferably from plants, subjecting the pure or partially pure O-methylated γ-mangostin to demethylation reaction procedure followed by purification of the said demethylated product to obtain pure γ-mangostin.

  一种制备γ-芒果皮素的工艺，包括以下步骤：从植物中制备O-甲基γ-芒果皮素，然后将纯或部分纯的O-甲基化的γ-芒果皮素经过脱甲基反应程序，并对所述脱甲基产物进行纯化以获得纯的γ-芒果皮素。
• 4-Fluorobiphenyl derivatives
  申请人：FUJIREBIO Inc.

  公开号：EP0617000A2

  公开（公告）日：1994-09-28

  A 4-fluorobiphenyl derivative of formula (I), which is useful as a cholesterol lowering agent or a lipid lowering agent because of its strong inhibitory effect on HMG-CoA reductase), and which is also useful as an intermediate for producing the above-mentioned cholesterol lowering agent or lipid lowering agent: wherein A is a ω-oxycarbonyldihydroxybutyl group, a tetrahydropyranyl group, a ω-oxycarbonyl-3-oxobutyl group, a formyl group, or a cyano group; R¹ is a halogen atom, an alkyl group, or a group represented by R⁵O-, wherein R⁵ is a hydrogen atom, or an alkyl group; R² is a hydrogen atom, an alkyl group; R³ is a hydrogen atom, or an alkyl group; R⁵ and R² may form a five-membered ring or a six-membered ring in combination with the oxygen atoms to which R⁵ and R² are respectively bonded, and R⁵ and R³ may form a five-membered ring or a six-membered ring in combination with the oxygen atom to which R⁵ is bonded.

  式（I）的 4-氟联苯衍生物，因其对 HMG-CoA 还原酶有很强的抑制作用，可用作降胆固醇剂或降血脂剂，也可用作生产上述降胆固醇剂或降血脂剂的中间体： 其中 A 是ω-氧羰基二羟基丁基、四氢吡喃基、ω-氧羰基-3-氧代丁基、甲酰基或氰基；R¹ 是卤素原子、烷基或由 R⁵O- 代表的基团，其中 R⁵ 是氢原子或烷基；R² 是氢原子、烷基；R³ 是氢原子或烷基；R⁵ 和 R² 可与分别与 R⁵ 和 R² 键合的氧原子结合形成五元环或六元环，R⁵ 和 R³ 可与与 R⁵ 键合的氧原子结合形成五元环或六元环。